BOULDER, Colo., Oct. 13, 2015 /PRNewswire/ -- ArcherDX, Inc., announced an addition to its target enrichment panel offering—the Archer™ Comprehensive Thyroid and Lung (CTL) Assay. This assay combines two complementary targeted NGS panels to detect gene fusions, point mutations, RNA abundance and copy number variations (CNVs) from FFPE and FNA lung and thyroid cancer samples.
"The CTL Assay is specifically designed to provide internal verification of several classes of driver mutations," said Josh Stahl, Vice President of R&D at ArcherDX. "By utilizing molecular-barcodes for quantitative analysis, we can examine both copy number variations and the corresponding changes in RNA abundance in a highly multiplexed NGS assay. Furthermore, adding expression-imbalance readout to this assay provides additional evidence supporting identified gene fusions."
The CTL Assay combines two RNA- and DNA-specific NGS library preparation panels that fully complement each other, providing internal mutations verification by comparing sequencing reads from both DNA and RNA input molecules.
"Lung cancer is one of the most deadly forms of cancer in the world, and thyroid cancer has one of the fastest growing incidence rates in the U.S." said Jason Myers, Ph.D., CEO of ArcherDX. "The overlap in targets in these diseases, especially for gene fusions, means that labs can batch samples more frequently and reduce sequencing costs."
Designed for use in high-throughput laboratories, the Archer CTL Assay employs simple, lyophilized workflows for NGS library preparation. Once sequenced, samples are analyzed using the complementary Archer Analysis software suite. Total turnaround time for running both CTL panels is 3-5 days, starting from sample extraction through sequencing and data reporting.
ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.
By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.
ArcherDX is headquartered in Boulder, Colo., and maintains manufacturing operations in Beverly, Mass.
Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.